Coya Therapeutics, Inc. (COYA)
$4.18-6.49%Close
SELLCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $76M
- Beta
- 0.58
- P/E (TTM)
- -3.91
- Short % float
- 6.79%
- Days to cover
- 7.0
- SI change
- +0.3%
- 1W
- -14.87%
- 1M
- -10.11%
- vs SPY 1W
- -13.89%
- vs SPY 1M
- -11.97%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 3
- VALUE
- 8
- GROWTH
- 15
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-32.0%
REV YoY-
ROE-53.3%
EPS YoY-
ROA-45.8%
GROSS100
OP-282
NET-270
[VALUATION]
P/E TTM-3.91
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B2.27
P/FCF-
EV/EBITDA-2.49
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO13.40
ND/EBITDA-
BETA0.58
Company news
FAQ
- What is LOPJLB’s current signal on COYA?
- LOPJLB’s latest quantitative signal on Coya Therapeutics, Inc. (COYA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is COYA in?
- Coya Therapeutics, Inc. (COYA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Coya Therapeutics, Inc. (COYA) do?
- Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101,…